Avacopan, the oral inhibitor of complement activation, yields significant sustained remission compared with standard treatment with steroids in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), the ADVOCATE study shows.
Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.
A single-dose of nirsevimab helps prevent respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in preterm infants during an entire RSV season, according to a recent study.
For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.
In highly viraemic mothers, initiating treatment with tenofovir alafenamide fumarate (TAF) at the 13th gestational week or later in pregnancy puts a lid on hepatitis B virus (HBV) and prevents vertical transmission when infants receive standard immunoprophylaxis, as shown in a study.
The addition of venetoclax to azacitidine improved survival and remission rates in previously untreated adults with acute myeloid leukaemia (AML) who were ineligible for intensive induction chemotherapy (CT), the VIALE-A trial has shown.
In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Adding mepolizumab to standard of care treatment significantly reduces nasal polyp size and obstruction in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the SYNAPSE* study presented at ERS 2020.
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.